Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCK | P08631 | 6/20 | 0.39 |
| ▸ | NR2C2 | P49116 | 6/20 | 0.39 |
| ▸ | BTK | Q06187 | 6/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.38 |
| ▸ | XDH | P47989 | 5/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930310 | 0.85 | CTSA (0.48) | XDH | |
| SCHEMBL2932710 | 0.84 | ATM (0.43) | HCKNR2C2BTKEPHA2XDH | |
| SCHEMBL2931726 | 0.83 | PSMB5 (0.51) | HDAC3HDAC1HDAC2 | |
| SCHEMBL2934031 | 0.81 | CTSS (0.42) | HCKNR2C2BTKEPHA2CTSB | |
| SCHEMBL606550 | 0.79 | CTSL (0.46) | CTSBCTSS | |
| SCHEMBL12190998 | 0.78 | XDH (0.59) | HCKNR2C2BTKEPHA2XDH | |
| SCHEMBL2933259 | 0.78 | LMNA (0.50) | NPC1RAB9ASMN1; SMN2HDAC1 | |
| SCHEMBL2932479 | 0.77 | ELANE (0.50) | CAMK2DNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12190988 | 0.75 | XDH (0.44) | HCKNR2C2BTKEPHA2XDH | |
| SCHEMBL619140 | 0.75 | HDAC8 (0.45) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | claimed |
| EP-1846424-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-01-27 | — | — | EP | claimed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | claimed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | claimed |
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| EP-1846424-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | HCK 4085/4885NR2C2 3301/4885BTK 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.